Zhonghua Jie He He Hu Xi Za Zhi. 2026 Mar 12;49(3):317-323. doi: 10.3760/cma.j.cn112147-20250610-00314.
ABSTRACT
Objective: This study aims to evaluate the clinical effectiveness of a modified balloon pulmonary angioplasty(BPA) procedure in the treatment of chronic thromboembolic pulmonary hypertension. Methods: We conducted a retrospective analysis of clinical data from patients diagnosed with chronic thromboembolic pulmonary hypertension who underwent Modified BPA at the Department of Cardiovascular Medicine in Xiamen Hospital of Traditional Chinese Medicine between January 2021 and May 2024. The study comprised 21 patients, including 5 males and 16 females, who successfully underwent the scheduled six BPA surgical sessions, totaling 126 individual cases. Results: All surgeries were guided by pressure guidewires. Three patients exhibited mild hemoptysis during the procedure, while two experienced mild pulmonary edema in the postoperative phase. There were no fatalities. Compared to the baseline, significant improvements were observed in indicators such as mean pulmonary artery pressure, pulmonary vascular resistance, and cardiac index following the surgical treatment course for all patients. These differences were statistically significant (P<0.001) as measured by right heart catheterization. Three months post-treatment, there was a marked improvement in cardiac function classification (WHO FC), 6-minute walking distance, and NT-proBNP levels compared to the baseline, with these differences also being statistically significant (P<0.001). Additionally, significant enhancements were noted in the right atrial area, estimated pulmonary artery systolic pressure, and tricuspid annular plane systolic excursion (TAPSE), all of which exhibited statistically significant differences (P<0.001). Conclusions: The modified BPA procedure significantly improves the structure of the right heart, cardiac function, and hemodynamics in patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH). This intervention is not only safe but also highly effective, positioning it as an exceptional therapeutic option for patients with CTEPH.
PMID:41820038 | DOI:10.3760/cma.j.cn112147-20250610-00314
